May CI van Schalkwyk

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

Scott Wilkie, May CI van Schalkwyk, Steve Hobbs et al. · Journal of Clinical Immunology · 2012 · 484 citations

Medicine, Cancer Biology, Oncology +12

A framework for identifying and mitigating the equity harms of COVID-19 policy interventions

R. E. Glover, May CI van Schalkwyk, Elie A. Akl et al. · Journal of Clinical Epidemiology · 2020 · 188 citations · Full text

Public Affairs, Health Policy, Public Policy +14

Dark Nudges and Sludge in Big Alcohol: Behavioral Economics, Cognitive Biases, and Alcohol Industry Corporate Social Responsibility

Mark Petticrew, Nason Maani, Luisa M Pettigrew et al. · Milbank Quarterly · 2020 · 140 citations · Full text

Public Health, Behavioral Sciences, Psychology +17

Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

May CI van Schalkwyk, Sophie Papa, Jean‐Pierre Jeannon et al. · Human Gene Therapy Clinical Development · 2013 · 123 citations

Medicine, Immunology, Oncology +17

Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells

David M. Davies, Julie Foster, Sjoukje J. C. van der Stegen et al. · Molecular Medicine · 2012 · 111 citations · Full text

Medicine, Immunology, Oncology +17